NYSEAMERICAN:NSRX Nasus Pharma (NSRX) Stock Price, News & Analysis $3.15 -0.24 (-7.08%) Closing price 05/8/2026 04:10 PM EasternExtended Trading$3.13 -0.02 (-0.63%) As of 05/8/2026 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartHeadlinesSEC FilingsBuy This Stock About Nasus Pharma Stock (NYSEAMERICAN:NSRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Nasus Pharma alerts:Sign Up Key Stats Today's Range$2.95▼$3.3950-Day Range$2.01▼$5.1052-Week Range$1.98▼$9.99Volume105,205 shsAverage Volume135,748 shsMarket Capitalization$36.89 millionP/E RatioN/ADividend YieldN/APrice Target$18.00Consensus RatingBuy Company Overview Nasus Pharma Ltd. is a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions. Nasus Pharma Ltd. is based in TEL AVIV, Israel. Read More Nasus Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreNSRX MarketRank™: Nasus Pharma scored higher than 44% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingNasus Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.Upside PotentialNasus Pharma has a consensus price target of $18.00, representing about 471.4% upside from its current price of $3.15.Amount of Analyst CoverageNasus Pharma has only been the subject of 1 research reports in the past 90 days.Read more about Nasus Pharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioNasus Pharma has a P/B Ratio of 10.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for NSRX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNasus Pharma does not currently pay a dividend.Dividend GrowthNasus Pharma does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A Search Interest3 people have searched for NSRX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows7 people have added Nasus Pharma to their MarketBeat watchlist in the last 30 days. Company Ownership2.9 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $10,904.00 in company stock, which represents 0.0296% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Nasus Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $10,904.00 in company stock and sold $0.00 in company stock.Percentage Held by InstitutionsNasus Pharma has minimal institutional ownership at this time.Read more about Nasus Pharma's insider trading history. Receive NSRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nasus Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NSRX Stock News HeadlinesNasus Pharma to Participate in Upcoming Investor ConferencesMay 1, 2026 | globenewswire.comNasus Pharma (NYSEAMERICAN:NSRX) CEO Dan Benjamin Teleman Purchases 2,900 SharesApril 24, 2026 | insidertrades.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.May 9 at 1:00 AM | Profits Run (Ad)Nasus Pharma Ltd. (NSRX) Institutional HoldingsApril 23, 2026 | nasdaq.comNasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business UpdateMarch 25, 2026 | globenewswire.comBriefCast Publishes Transcript: Nasus Pharma NS002 Phase 2 Positive Topline Results Webinar TranscriptMarch 19, 2026 | globenewswire.comNasus Pharma Stock Hits 52-Week Low - Here's WhyMarch 16, 2026 | benzinga.comNasus Pharma’s NS002 Outperforms EpiPen in Phase 2 Anaphylaxis Study, Pivotal Trial Planned for Late 2026March 16, 2026 | tipranks.comSee More Headlines NSRX Stock Analysis - Frequently Asked Questions How have NSRX shares performed this year? Nasus Pharma's stock was trading at $7.10 on January 1st, 2026. Since then, NSRX shares have decreased by 55.6% and is now trading at $3.15. How do I buy shares of Nasus Pharma? Shares of NSRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today5/09/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNYSEAMERICAN:NSRX CIK2029039 Webwww.nasus-pharma.com Phone972-3573-6632FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for Nasus Pharma$18.00 High Price Target$18.00 Low Price Target$18.00 Potential Upside/Downside+471.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio2.24 Quick Ratio2.24 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.31 per share Price / Book10.16Miscellaneous Outstanding Shares11,710,000Free FloatN/AMarket Cap$36.89 million OptionableN/A BetaN/A Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NYSEAMERICAN:NSRX) was last updated on 5/9/2026 by MarketBeat.com Staff. From Our PartnersYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredTrade this between 9:30 and 10:45 am ESTThe first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredElon Unveils AI Passive Income Stream for Millions of AmericansDuring Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...InvestorPlace | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredInvest in SpaceX Before IPOSpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...NXT Wave Research | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nasus Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nasus Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
